Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lifted by Rockland Trust Co.

Rockland Trust Co. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 2.1% during the first quarter, HoldingsChannel.com reports. The firm owned 3,045 shares of the medical research company’s stock after acquiring an additional 64 shares during the period. Rockland Trust Co.’s holdings in Amgen were worth $866,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. BOK Financial Private Wealth Inc. purchased a new position in Amgen during the fourth quarter valued at approximately $29,000. United Community Bank bought a new stake in Amgen in the fourth quarter worth approximately $29,000. Providence Capital Advisors LLC bought a new stake in Amgen in the third quarter worth approximately $30,000. Planned Solutions Inc. bought a new stake in Amgen in the fourth quarter worth approximately $30,000. Finally, Delos Wealth Advisors LLC grew its position in Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after acquiring an additional 100 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 0.6 %

Shares of NASDAQ:AMGN opened at $308.16 on Friday. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The company’s fifty day moving average is $296.57 and its 200-day moving average is $290.69. The company has a market capitalization of $165.31 billion, a PE ratio of 44.02, a P/E/G ratio of 2.80 and a beta of 0.60.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same quarter in the previous year, the company earned $3.98 EPS. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.69% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on AMGN. Morgan Stanley boosted their target price on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. TD Cowen decreased their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Royal Bank of Canada boosted their price objective on shares of Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research note on Friday, June 14th. Finally, Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $305.85.

View Our Latest Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.